These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 26089238)

  • 1. Unraveling the Complexities of Treating Metastatic Colorectal Cancer With Angiogenesis Inhibitors.
    Overstreet K; Van Cutsem E; Johnson M
    Clin Colorectal Cancer; 2015 Sep; 14(3):131-2. PubMed ID: 26089238
    [No Abstract]   [Full Text] [Related]  

  • 2. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.
    Myint ZW; Sen JM; Watts NL; Druzgal TJ; Nathan BR; Ward MD; Boyer JE; Fracasso PM
    Clin Colorectal Cancer; 2014 Jun; 13(2):127-30. PubMed ID: 24461491
    [No Abstract]   [Full Text] [Related]  

  • 3. Regorafenib in metastatic colorectal cancer.
    Sartore-Bianchi A; Zeppellini A; Amatu A; Ricotta R; Bencardino K; Siena S
    Expert Rev Anticancer Ther; 2014 Mar; 14(3):255-65. PubMed ID: 24559322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of bevacizumab with fluoropyrimidine-based regimens for first-line treatment of metastatic colorectal cancer.
    Tyagi P
    Clin Colorectal Cancer; 2006 Sep; 6(3):189-91. PubMed ID: 17026787
    [No Abstract]   [Full Text] [Related]  

  • 5. Tenth anniversary of bevacizumab in colorectal cancer: has it fulfilled its promise?
    Salazar R; Grasselli J; Santos C; Tabernero J
    Future Oncol; 2014 Feb; 10(2):149-52. PubMed ID: 24490598
    [No Abstract]   [Full Text] [Related]  

  • 6. Metastatic colorectal cancer.
    Prescrire Int; 2017 Feb; 26(179):51. PubMed ID: 30726636
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of new agents in the treatment of colorectal cancer.
    Ruiz de Erenchun F
    Oncology; 2005; 68(2-3):162; author reply 162. PubMed ID: 16097096
    [No Abstract]   [Full Text] [Related]  

  • 8. Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer.
    Hendifar A; Tan CR; Annamalai A; Tuli R
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):1051-61. PubMed ID: 24898788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting--its impact on clinical practice.
    Goel G; Sun W
    J Hematol Oncol; 2015 Jul; 8():92. PubMed ID: 26215324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing toxicities associated with antiangiogenic biologic agents in combination with chemotherapy for metastatic colorectal cancer.
    Grenon NN
    Clin J Oncol Nurs; 2013 Aug; 17(4):425-33. PubMed ID: 23899982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation.
    Giampieri R; Scartozzi M; Del Prete M; Maccaroni E; Bittoni A; Faloppi L; Bianconi M; Cecchini L; Cascinu S
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):272-83. PubMed ID: 23806981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating endothelial cells and their subpopulations: role as predictive biomarkers in antiangiogenic therapy for colorectal cancer.
    Manzoni M; Comolli G; Torchio M; Mazzini G; Danova M
    Clin Colorectal Cancer; 2015 Mar; 14(1):11-7. PubMed ID: 25591800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.
    Malik Z; Eng C
    Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):4-7. PubMed ID: 17491584
    [No Abstract]   [Full Text] [Related]  

  • 14. Colorectal cancer: targeting metastasis and angiogenesis.
    Chu E
    Clin Colorectal Cancer; 2002 Feb; 1(4):200. PubMed ID: 12450417
    [No Abstract]   [Full Text] [Related]  

  • 15. Apoptosis and chemo-resistance in colorectal cancer.
    Prabhudesai SG; Rekhraj S; Roberts G; Darzi AW; Ziprin P
    J Surg Oncol; 2007 Jul; 96(1):77-88. PubMed ID: 17443738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer.
    Giampieri R; Scartozzi M; Del Prete M; Fulli A; Faloppi L; Bianconi M; Maccaroni E; Cascinu S
    Cancer Treat Rev; 2014 Sep; 40(8):934-41. PubMed ID: 24997679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer.
    Khoja L; Kumaran G; Zee YK; Murukesh N; Swindell R; Saunders MP; Clamp AR; Valle JW; Wilson G; Jayson GC; Hasan J
    J Clin Gastroenterol; 2014; 48(5):430-4. PubMed ID: 24153157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to Manage the Side Effects of New Targets Agents for Metastatic Colorectal Cancer.
    Becze E
    ONS Connect; 2016 Jan; 31(1):24-5. PubMed ID: 26887105
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel chemotherapeutic and targeted agents in metastatic colorectal cancer: the time has arrived.
    O'Neil BH; Goldberg RM
    Expert Opin Investig Drugs; 2003 Dec; 12(12):1939-49. PubMed ID: 14640938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of angiogenesis inhibitors in the treatment of colorectal cancer].
    Bodoky G
    Magy Onkol; 2007; 51(2):139-44. PubMed ID: 17660870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.